Are Immune Therapies for Type 1 Diabetes Worthwhile?

Source link :

The oral Janus kinase inhibitor baricitinib (Olumiant) preserved beta-cell function in people with new-onset type 1 diabetes over 48 weeks, new phase 2 data show. But, as with the intravenously administered monoclonal antibody teplizumab (Tzield), there were no significant improvements in A1c and all study participants continued to require exogenous insulin. Both drugs are currently […]

Author : News Health

Publish date : 2023-12-06 22:05:00

Copyright for syndicated content belongs to the linked Source.